Drugs / SBT6290
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05234606 | Mar 2022 | head and neck squamous cell carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, triple-negative breast carcinoma +1 | Silverback Therapeutics | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBT6290 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05234606 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) injection” NCT05234606 ↗ |